This study evaluates TL-895, a potent, orally-available and highly selective irreversible
tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must be
relapsed/refractory (e.g., having failed prior therapy), intolerant, or ineligible to receive
JAKi treatment.